BRPI0507326A - formulação sólida de ação retardada para administração parenteral - Google Patents

formulação sólida de ação retardada para administração parenteral

Info

Publication number
BRPI0507326A
BRPI0507326A BRPI0507326-0A BRPI0507326A BRPI0507326A BR PI0507326 A BRPI0507326 A BR PI0507326A BR PI0507326 A BRPI0507326 A BR PI0507326A BR PI0507326 A BRPI0507326 A BR PI0507326A
Authority
BR
Brazil
Prior art keywords
formulation
parenteral administration
acetate
triptorelin acetate
excipient
Prior art date
Application number
BRPI0507326-0A
Other languages
English (en)
Inventor
Francesc Navarro Pujol
Roland Cherif-Cheikh
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Publication of BRPI0507326A publication Critical patent/BRPI0507326A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

"FORMULAçãO SóLIDA DE AçãO RETARDADA PARA ADMINISTRAçãO PARENTERAL" A invenção refere-se em particular a uma formulação sólida de ação retardada para administração parenteral compreendendo: a ) acetado de triptorelina, e b) um ou mais excipientes compreendendo um polímero ou copolímero de ácido láctico e/ou de ácido glicólico ou uma mistura de polímeros e/ou copolímeros de ácido láctico e/ou de ácido glicólico, a dita formação contendo de 10 a 99% de acetado de triptorelina em peso em relação ao peso total da formulação e sendo obtida por um processo comportando a fusão da mistura do acetado de triptorelina e do ou dos excipientes quando da fusão-extrusão do acetado de triptorelina com o ou os excipientes, a dita formulação sendo tal qual que ela libera o acetado de triptorelina em uma duração de ao menos uma semana uma vez administrada pela via parenteral um paciente.
BRPI0507326-0A 2004-02-05 2005-02-04 formulação sólida de ação retardada para administração parenteral BRPI0507326A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0401109A FR2865938B1 (fr) 2004-02-05 2004-02-05 Formulation retard solide comprenant de l'acetate de triptoreline
PCT/FR2005/000248 WO2005082418A1 (fr) 2004-02-05 2005-02-04 Formulation retard solide comprenant de l’acetate de triporeline

Publications (1)

Publication Number Publication Date
BRPI0507326A true BRPI0507326A (pt) 2007-07-03

Family

ID=34778533

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507326-0A BRPI0507326A (pt) 2004-02-05 2005-02-04 formulação sólida de ação retardada para administração parenteral

Country Status (13)

Country Link
US (1) US20070031500A1 (pt)
EP (1) EP1722820A1 (pt)
JP (1) JP2007520533A (pt)
CN (1) CN1913924B (pt)
AR (1) AR047797A1 (pt)
BR (1) BRPI0507326A (pt)
CA (1) CA2554870A1 (pt)
FR (1) FR2865938B1 (pt)
IL (1) IL176786A0 (pt)
MX (1) MXPA06008617A (pt)
RU (1) RU2399384C2 (pt)
TW (1) TWI399224B (pt)
WO (1) WO2005082418A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005035717A2 (en) 2003-10-03 2005-04-21 Thorn Bioscience, Llc Process for the synchronization of ovulation for timed breeding without heat detection
JP5419169B2 (ja) * 2007-06-06 2014-02-19 デビオファーム リサーチ アンド マニュファクチャリング ソシエテ アノニム 微小粒子で構成される徐放性医薬組成物
RU2568839C2 (ru) 2009-04-23 2015-11-20 ДжейБиЭс Юнайтид Энимал Хэлс II ЛЛК Способ и композиция для синхронизации времени осеменения
EP2246063A1 (en) * 2009-04-29 2010-11-03 Ipsen Pharma S.A.S. Sustained release formulations comprising GnRH analogues
CN102048699B (zh) * 2009-11-03 2012-11-07 长春金赛药业有限责任公司 一种注射用醋酸曲普瑞林的缓释微球的制备方法
US20140335135A1 (en) * 2011-12-05 2014-11-13 Ferring Bv Pharmaceutical composition
EP2925339B1 (en) 2012-11-28 2020-04-29 United-AH II, LLC Method for synchronizing time of insemination in gilts
CN105267153B (zh) * 2015-11-27 2018-05-11 上海苏豪逸明制药有限公司 一种曲普瑞林缓释微粒及其制备方法
CN105878174B (zh) * 2016-04-26 2021-06-29 广州帝奇医药技术有限公司 一种固体分散体及其制备方法与应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH679207A5 (pt) * 1989-07-28 1992-01-15 Debiopharm Sa
GB2246514B (en) * 1990-08-01 1993-12-15 Scras Sustained release pharmaceutical compositions and the preparation of particles for use therein
GB9016885D0 (en) * 1990-08-01 1990-09-12 Scras Sustained release pharmaceutical compositions
DE4223169C1 (de) * 1992-07-10 1993-11-25 Ferring Arzneimittel Gmbh Verfahren zur Mikroverkapselung wasserlöslicher Wirkstoffe
US5569467A (en) * 1993-05-15 1996-10-29 Societe De Conseils De Recherches Et D'applications (S.C.R.A.S.) Process for the preparation of microballs and microballs thus obtained
DE19617137C1 (de) * 1996-04-29 1997-02-27 Henkel Kgaa Verwendung von Copolymerestern für die Herstellung von Mikrosphären
US5945128A (en) * 1996-09-04 1999-08-31 Romano Deghenghi Process to manufacture implants containing bioactive peptides
US20020111603A1 (en) * 1996-12-02 2002-08-15 Societe De Conseils De Recherches Et D'application Device for local administration of solid or semi-solid formulations and delayed-release formulations for proposal parental administration and preparation process
FR2756493B1 (fr) * 1996-12-02 2001-04-13 Delab Dispositif d'administration locale de formulations solides ou semi-solides
IT1304152B1 (it) * 1998-12-10 2001-03-08 Mediolanum Farmaceutici Srl Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato
WO2002058672A2 (en) * 2001-01-26 2002-08-01 Debio Recherche Pharmaceutique S.A. Microparticles of biodegradable polymer encapsulating a biologically active substance
GB0122113D0 (en) * 2001-09-11 2001-10-31 Astrazeneca Ab Composition

Also Published As

Publication number Publication date
JP2007520533A (ja) 2007-07-26
CN1913924B (zh) 2011-11-09
FR2865938A1 (fr) 2005-08-12
AR047797A1 (es) 2006-02-22
RU2399384C2 (ru) 2010-09-20
CA2554870A1 (fr) 2005-09-09
TWI399224B (zh) 2013-06-21
RU2006131705A (ru) 2008-03-10
HK1101127A1 (en) 2007-10-12
EP1722820A1 (fr) 2006-11-22
MXPA06008617A (es) 2006-08-28
CN1913924A (zh) 2007-02-14
WO2005082418A1 (fr) 2005-09-09
TW200528143A (en) 2005-09-01
US20070031500A1 (en) 2007-02-08
IL176786A0 (en) 2006-10-31
FR2865938B1 (fr) 2006-06-02

Similar Documents

Publication Publication Date Title
Gilron Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions
Morton et al. Analgesic efficacy of paracetamol and diclofenac in children receiving PCA morphine.
Yamagata et al. Characterization of insulin protection properties of complexation hydrogels in gastric and intestinal enzyme fluids
Weinbroum et al. Dextromethorphan and dexmedetomidine: new agents for the control of perioperative pain
BR112014011504A2 (pt) forma de dosagem farmacêutica oral inviolável compreendendo ingrediente farmacologicamente ativo, antagonista opioide e/ou agente aversivo, óxido de polialquileno e polímero aniônico
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
ATE382337T1 (de) Bioabsorbierbare pharmazeutische zusammensetzung enthaltend einen plga-copolymer
BRPI0507326A (pt) formulação sólida de ação retardada para administração parenteral
BR0308989A (pt) Formulações de claritromicina com biodisponibilidade aperfeiçoada e processo de preparação das mesmas
ZA202500860B (en) Pharmaceutical composition for resisting infection with sars-cov-2 or mutant thereof, and combined drug thereof
WO2008039406A3 (en) Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
JP2009256349A (ja) 錠剤
JP2016512247A5 (pt)
BRPI0510738A (pt) métodos de tratar doenças com copolìmeros aleatórios
WO2021222584A3 (en) Inhibition of sars-cov-2 viral entry through administration of lactoferrin and uses thereof
JP2020526525A5 (pt)
RU2006137349A (ru) Композиции продолжительного действия на основе налтрексона
WO2004078111A3 (en) Extended release minocycline compositions and processes for their preparation
Wilder et al. NG-nitro-L-arginine methyl ester (L-NAME) prevents tachyphylaxis to local anesthetics in a dose-dependent manner
Nesek Adam et al. Pain management in critically ill patients
Xie et al. Intravenous infusion of lidocaine can accelerate postoperative early recovery in patients undergoing surgery for obstructive sleep apnea
BRPI0415322A (pt) composição farmacêutica antiretroviral, processo para a preparação de uma composição farmacêutica antiretroviral, método para reduzir a carga de consumo de pìlulas para um paciente, método para aumentar a meia-vida in vivo de lamivudina e de zidovudina enquanto não afetando a meia-vida de nevirapina
BRPI0510855A (pt) medicamento em forma de pelìcula para ministração oral e uso de estriol e/ou de ésteres de estriol farmaceuticamente aceitáveis
Hwang et al. Effect of different doses of ketamine with low-dose rocuronium on intubation conditions in children: prospective randomized double blind trial
EA200601283A1 (ru) Фармацевтическая композиция с контролируемым высвобождением, содержащая нерастворимый в кислотах полимер и биоадгезивный полимер

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: IPSEN PHARMA S.A.S. (FR)

B25G Requested change of headquarter approved

Owner name: IPSEN PHARMA S.A.S. (FR)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2308 DE 31/03/2015.